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e aim of this study was to assess cross-sectional and longitudinal correlations between uEPX and othermarkers of asthma control
and eosinophilic airway in�ammation.Methods.Wemeasured uEPX at baseline, aer 1 year and aer 2 years in 205 atopic asthmatic
children using inhaled �uticasone. At the same time points, we assessed symptom scores (2 weeks diary card), lung function (forced
expiratory volume in one second (FEV1)), airway hyperresponsiveness (AHR), and percentage eosinophils in induced sputum
(% eos). Results. We found negative correlations between uEPX and FEV1 at baseline (𝑟𝑟 𝑟 𝑟𝑟𝑟1𝑟, 𝑃𝑃 𝑟 𝑟𝑟𝑟1), aer 1 year (𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟𝑟,
𝑃𝑃 𝑃 𝑟𝑟𝑟1) and aer 2 years (𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟1,𝑃𝑃 𝑟 𝑟𝑟𝑟𝑟).Within-patient changes of uEPX showed a negative association with FEV1 changes
(at 1 year: 𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟𝑟, 𝑃𝑃 𝑟 𝑟𝑟𝑟1 ; at 2 years: 𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟1, 𝑃𝑃 𝑟 𝑟𝑟𝑟𝑃). Within-patient changes from baseline of uEPX correlated with
changes in % eos. No relations were found between uEPX and symptoms. Conclusion. In this population of children with atopic
asthma, uEPX correlated with FEV1 and% eos, andwithin-subjects changes in uEPX correlated with changes in FEV1 and% eos. As
the associations were weak and the scatter of uEPX wide, it seems unlikely that uEPX will be useful as a biomarker for monitoring
asthma control in the individual child.
1. Introduction
Eosinophilic protein X is produced by activated eosinophils
and can be measured in blood, stools, and urine (uEPX)
[1, 2]. Elevated uEPX has been reported in asthmatics with
or without allergy [3, 4], with great overlap between healthy
controls and asthmatics [5, 6]. A relation with asthma
symptoms and lung function has been shown, and uEPX
increases signi�cantly during asthma exacerbations [7–9]. A
reduction in uEPX has been reported aer starting inhaled
corticosteroids [10]. erefore, it has been suggested that
measuring urinary EPX may be useful for monitoring the
eﬀect of ICS in asthma [3, 10, 11].
Since measuring uEPX is completely noninvasive and
independent of patient’s cooperation, it has the potential
to be a feasible tool in asthma management in young
children. Several studies have demonstrated cross-sectional
correlations between uEPX and conventional clinical mark-
ers of asthma control and airway in�ammation [3, 4, 12].
Previously, we reported these cross-sectional data measured
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at baseline in part of the present study population [13]. Data
on longitudinal changes in uEPXwithin subjects compared to
changes inmarkers of asthma control or airway in�ammation
were examined in only one study in 14 children [3].
We analysed cross-sectional and longitudinal uEPX data
from a long-term follow-up study in children with atopic
asthma [14]. We hypothesised that changes in uEPX would
be related to changes eosinophilic airway in�ammation and
could provide information that is additional to symptoms and
lung function.
2. Methods
2.1. Subjects. Asthmatic children took part in a randomised
controlled multicentre trial (CATO: Children Asthma er-
apy Optimal) reported in detail previously [14]. Brie�y, 288
children with a documented clinical history of moderately
severe asthma were recruited from 15 paediatric clinics
including 7 university hospitals in the Netherlands. Al
patients had a positive, class 1, or more radioallergosorbent
test result for one or more airborne allergens.
During a run-in phase, all patients were treated with 100
or 250 𝜇𝜇g �uticasone bid depending on their equivalent treat-
ment before the study. Children were selected on the basis of
symptoms and/or AHR, and 210 children were randomised
to a reference strategy (adjustment of treatment on symptom
score) or an AHR strategy (treatment adjusted on the basis
of AHR and symptom score). During the 2-year follow-
up study, 3 monthly visits were performed. At each visit
symptoms scores (diary card over the last 2 weeks), forced
expiratory volume in one second (FEV1), and methacholine
challenge results were obtained, and medication (�ve levels:
�uticasone 100 or 200𝜇𝜇g per day or �uticasone/salmeterol
200/100, 500/100, or 1000/100 𝜇𝜇g per day (FlixotideDiskus or
Seretide Diskus, GlaxoSmithKline, UK) adjusted according
to the algorithms of the reference- and AHR strategy.
For the present study, �baseline� is de�ned as themoment
of randomisation for the CATO study.
2.2. Symptom Scores. Patients �lled in a diary card daily
during 2 weeks before each 3-month visit. Cough, shortness
of breath, and wheezing during night and day were recorded
on a 4 point scale (0 = no symptoms to 3 = severe symptoms
interfering with activity or sleep) [15]. e percentage of
symptom-free days de�ned as score 0 for cough, wheeze, and
shortness of breath was calculated.
2.3. AHR and Spirometry. were measured during each clinic
visit [16]. Studymedication was stopped 36 hours before lung
function and AHR testing. AHR was tested by methacholine
challenge using a dosimeter method [17]. e provocation
dose causing a 20% fall in FEV1 from baseline (PD20) was cal-
culated from a log dose-response plot by linear interpolation.
2.4. Sputum Induction and Processing. Sputum induction was
attempted in 8 of the 15 participating centres. Sputum was
induced according to a standardised method by inhaling an
aerosol of hypertonic sodium chloride 4.5%w/v [18, 19].
Diﬀerential cell counts of cytospins were performed and
samples containing more than 80% squamous cells were
excluded from the analysis [18].
2.5. Urinary Eosinophil Protein X. Spot samples of urine were
collected at randomisation (= baseline), aer a treatment
period of 1 year, and aer 2 years (the end of the study),
and immediately stored at −20∘C. EPX was determined using
a commercial enzyme-linked immunosorbent assay (ELISA)
for human EPX in 50-fold diluted samples (Medical and
Biological Laboratories, Nakaku Nagoya, Japan). e essay’s
sensitivity was 0.62 ng/mL. Urinary creatinine levels were
measured by the alkaline picratemethod (Roche,Mannheim,
Germany). Urinary EPX concentrations were expressed as 𝜇𝜇g
per mmol creatinine.
2.6. Statistical Analysis. Repeated measurements Anova was
used to evaluate associations between the various markers
anduEPX levels.e samemethodwas used to assess changes
from baseline. With this method (SAS PROC MIXED) the
information about the associations at the diﬀerent study time
points can be combined and the method allows for uEPX
not being available at all three time points for each patient.
In these analyses, uEPX values, % eosinophils in sputum,
and �uticasone doses were transformed logarithmically in
order to get approximate normal distributions and to reduce
the eﬀect of outlying observations, and consequently results
for these parameters are expressed as geometric means.
Percentage eosinophil values equal to 0 were replaced by
0.1% in order to allow the logarithmic transformation. In a
substantial part of the study population, especially at time
points T1 and T2, PD20 was higher than the highest dose
methacholine used (1570 𝜇𝜇g). For that reason PD20 data were
arbitrarily dichotomized in non-AHR (PD20 > 300 𝜇𝜇g) and
AHR (PD20 < 300 𝜇𝜇g). Correlation coeﬃcients calculated
at the diﬀerent time points are Spearman’s rank correlations.
𝑃𝑃 = 0𝑃0𝑃 (two-sided) was considered the limit of signi�cance.
3. Results
Urinary EPX was measured at least once in 205 children.
Patient characteristics at baseline are given in Table 1. In total
461, uEPX samples were analysed during the study. During
the 2-year treatment period, the geometric mean uEPX
signi�cantly decreased from 159 𝜇𝜇g/mmol to 104𝜇𝜇g/mmol
(𝑃𝑃 < 0𝑃001) (Figure 1). Anova showed a signi�cant treatment
eﬀect aer 1 year: in the AHR strategy group, uEPX had
decreased signi�cantly more than in the reference strategy
group, with a 29% lower geometric mean EPX level at that
time point (𝑃𝑃 = 0𝑃03). No treatment eﬀect was found at
year 2 (𝑃𝑃 = 0𝑃2𝑃). Further analysis showed that at 1 year,
there was a signi�cant �uticasone dose eﬀect, and this eﬀect
was not found at baseline or at year 2. At 1 year a twofold
higher dose was associated with a 25% lower uEPX level
(95%CI: 15%–34%; 𝑃𝑃 < 0𝑃001). Children treated according
to the AHR strategy had received signi�cantly higher doses of
�uticasone at 1 year (geometricmeans 580 versus 412 ug/day;
Mann-Whitney test, 𝑃𝑃 = 0𝑃01). Aer adjustment for the
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T 1: Characteristics of the 205 children at baseline.
Age (y) 10.4 [6.4–16.8]
Gender (m/f) 118/87
Daily dose �uticasone 200 𝜇𝜇g/500 𝜇𝜇g 116/89
uEPX (𝜇𝜇g/mmol creatinine) (𝑛𝑛 𝑛 𝑛𝑛𝑛) 184 (2–3114)
Symptom-free days (%) 50 (0–100)
FEV1 (% pred) 97 (56–136)
PD20 methacholine (𝜇𝜇g) 72 (1–>1570.0#)
Sputum eosinophils (%) (𝑛𝑛 𝑛 𝑛𝑛)† 1 (0–72)
Values are median (range).
FEV1: forced expiratory volume in 1 second; PD20 methacholine: provoca-
tive dose of methacholine causing FEV1 fall 20% from baseline.
#12 children had not reached the 20% fall at the highest dose of 1570 𝜇𝜇g.
†79 patients had a total of 127% eos measurements combined with an uEPX
measurement, and in 49 of these a baseline measurement was available.
Baseline characteristics form part of this group have been published previ-



















F 1: uEPX levels. Geometric mean uEPX (per mmol creati-
nine) levels with 95 percent con�dence intervals by measurement
visit (Anova estimates). T0: baseline; T1: aer a treatment period of
1 year; T2: aer a treatment period of 2 years. T1 versus T0:𝑃𝑃 𝑛 𝑛𝑃𝑛𝑛;
T2 versus T1: 𝑃𝑃 𝑛 𝑛𝑃𝑛𝑛; T2 versus T0: 𝑃𝑃 𝑃 𝑛𝑃𝑛𝑛𝑛.
higher dose using Anova, no signi�cant treatment eﬀect
remained.
3.1. Urinary EPX versus Parameters of Asthma Control (Tables
2 and 3). No correlations were found between uEPX and
the percentage symptom-free days or changes in uEPX and
changes in percentage symptom-free days. Anova also did
not show signi�cant associations. Cross-sectional analysis
showed weak negative correlations of the levels of uEPX and
FEV𝑛 (baseline: 𝑟𝑟 𝑛 𝑟𝑛𝑃𝑛𝑛, 𝑃𝑃 𝑛 𝑛𝑃𝑛𝑃; at 1 year: 𝑟𝑟 𝑛 𝑟𝑛𝑃𝑃𝑟𝑟 𝑃𝑃 𝑛
𝑛𝑃𝑛𝑛𝑃; at 2 years: 𝑟𝑟 𝑛 𝑟𝑛𝑃𝑃𝑛𝑟 𝑃𝑃 𝑛 𝑛𝑃𝑛𝑛𝑟, resp.). Anova showed




Symptom-free days (%) T1 0.03 0.68
T2 0.09 0.34
T0 𝑟0.18 0.01
FEV1 (% pred) T1 𝑟0.25 𝑃0.01
T2 𝑟0.22 0.02
T0 0.19 0.19
Sputum eosinophils (%) T1 0.19 0.20
T2 0.51 𝑃0.01
T0 𝑟0.14 0.08
PD20 methacholine (𝜇𝜇g) T1 𝑟0.20 0.02
T2 𝑟0.14 0.14
T0: at baseline; T1: aer a treatment period of 1 year; T2: aer a treatment
period of 2 years; FEV1: forced expiratory volume in 1 second. Numbers
evaluated for sputum eosinophils at T0, T1, and T2 are 49, 45, and 33,
respectively. Data shown represent Spearman rank correlation coeﬃcients.
Correlations at baseline (T0) in part of this group have been published
previously in a cross-sectional study (Nuijsink et al. [13]).
T 3: Correlations between the changes from baseline in uEPX
and changes in clinical markers of asthma control.
𝑟𝑟 𝑃𝑃 value





Sputum eosinophils (%) T1 0.10 0.64
T2 0.40 0.11
T0: at baseline; T1: aer a treatment period of 1 year; T2: aer a treatment
period of 2 years. FEV1: forced expiratory volume in 1 second.e individual
changes from baseline of uEPX and % eos are expressed as ratios. For
FEV1 and symptom-free days, the changes are expressed as the absolute
diﬀerences of the measured percentages. Numbers evaluable for the change
from baseline of% eos at T1 and T2 are 23 and 17, respectively. Data shown
are Spearman rank correlations.
that the signi�cant associations did not diﬀer between the
three time points and adjusting for ICS dose did not change
this. Also the changes from baseline of uEPX and FEV𝑛 were
signi�cantly related with each other (at 1 year 𝑟𝑟 𝑛 𝑟𝑛𝑃𝑃𝑛,
𝑃𝑃 𝑛 𝑛𝑃𝑛𝑛 and at 2 years; 𝑟𝑟 𝑛 𝑟𝑛𝑃𝑃𝑛𝑟 𝑃𝑃 𝑛 𝑛𝑃𝑛𝑟) (Figure
2). As compared to baseline, a tenfold increase in uEPX was
associated with a decrease of FEV𝑛 (% pred) of 2.8 percentage
points (95%CI : 0.3 to 5.3; 𝑃𝑃 𝑛 𝑛𝑃𝑛𝑃𝑟) and this decrease did
not signi�cantly diﬀer between the two time points (𝑃𝑃 𝑛
𝑛𝑃𝑟𝑟). A similar result was found when changes from the
previous assessment were evaluated.
At all visits, uEPX levels were higher in patients withAHR
(PD𝑃𝑛 methacholine 𝑃 300𝜇𝜇g methacholine) than in patients
without AHR. At 1 year this diﬀerence was statistically
signi�cant, with 13% higher uEPX in patients with AHR






















F 2: Scatterplot of within-patient changes from baseline in
forced expiratory volume in 1 second versus changes in uEPX.
Squares and the solid regression line pertain to changes between
baseline and 1-year-followup; asterisks and the dashed line represent
changes between baseline and 2 years. Changes of uEPX are shown
as ratios; changes of FEV1 are shown as absolute diﬀerences of
percentage predicted values.
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃) (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, 𝑃𝑃 𝑃 𝑃𝑃1𝑃, resp., at baseline and
aer 2 years treatment).is eﬀect remained aer adjustment
for dose. With regard to percentage eosinophils in sputum
a signi�cant correlation with uEPX was found at 2 years
(𝑟𝑟 𝑃 𝑃𝑃𝑟1, 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃1, 𝑛𝑛 𝑃 𝑛𝑛). Anova showed a signi�cant
overall association between uEPX and percentage sputum
eosinophils. A twofold higher value of sputum eosinophils
was associated with a 14% increased value of uEPX (95%CI:
6%–22%; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃1), and this relation did not signi�cantly
diﬀer between the 3 time points (𝑃𝑃 𝑃 𝑃𝑃11), nor was
the relation aﬀected by ICS dose. Although changes from
baseline of uEPX and percentage sputum eosinophils did not
signi�cantly correlate with each other at the separate time
points, a signi�cant relation was found combining both time
points using Anova. A within-patient doubling of sputum
eosinophils was associated with a mean increase of uEPX of
16% (95%CI: 0.1%–36%; 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃), and the ICS dose did
not aﬀect this relation.e individual variations however are
large (Figure 3).
4. Discussion
We prospectively assessed changes in uEPX in relation to
changes in asthma control within subjects over an obser-
vation period of 2 years. We found in atopic asthmatic
children that changes in uEPX measured aer 1 and 2 years
related signi�cantly with changes in FEV1 and % sputum
eosinophils, but not with changes in symptoms. Changes in
uEPX correlated with changes in ICS dose.
Con�icting data have been reported about cross-sectional





























F 3: Scatterplot of within-patient changes from baseline in
uEPX versus changes in percentage sputum eosinophils. Squares
and the solid regression line pertain to the changes between baseline
and 1 year (𝑛𝑛 𝑃 𝑛𝑛); asterisks and the dashed line represent changes
between baseline and 2 years (𝑛𝑛 𝑃 1𝑛). Changes of uEPX and
percentage sputum eosinophils are both shown as ratios.
described the results of cross-sectional analysis at baseline in
the present study population [13]. We found a weak inverse
correlation between uEPX and FEV1. With the present study,
we con�rmed the relation between uEPX and FEV1 at
diﬀerent time points. Moreover, we showed that changes
in uEPX and changes FEV1 were related. is is in line
with the signi�cant correlation between these parameters
found by Lugosi et al. in 14 asthmatic children [3]. However
the interval of their measurements was much shorter (1-
2 months). It has been shown that correlations between
eosinophilic airway in�ammation and lung function areweak
andmay only reach signi�cance in large populations [4, 6, 20,
21]. Clearly FEV1 is dependent on many more factors than
eosinophilic in�ammation alone.
e correlation between uEPX and sputum eosinophils
was weak, and this is in line with the relations between
sputum ECP, sputum eosinophils, and uEPX described by
Mattes et al. [12].Weak correlations seem to be the rule when
diﬀerent markers of eosinophilic in�ammation are compared
[22]. Moreover, uEPX is secreted by activated eosinophils,
and it is therefore possible that uEPX provides information
about eosinophil activation rather than numbers.
We found no relation between uEPX and symptoms. A
signi�cant relation between uEPX and symptoms has been
described during acute asthma exacerbations, spontaneously
or provoked by ICS withdrawal [23]. Also, signi�cantly
higher uEPX levels were found in symptomatic asthmatic
children than in asymptomatic children [1, 3, 4]. However,
a 6-month follow-up study in 14 children with mild asthma
found, no signi�cant association was found [9]. So the
severity of symptoms should be taken into account when
correlating uEPX and symptoms. In our study population, the
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symptom scores were low and this may explain the apparent
discrepancy with these previous studies. It could well be that
relations between uEPX and parameters of asthma control
could have been in�uenced by other factors as well, including
seasonal variations, severity of allergy, and asthma and atopic
dermatitis [24, 25].e use of varying doses of ICS is another
possibility, for which we have corrected.
What are the clinical implications of our �ndings? As
uEPX does not correlate with symptoms, but does correlate
with sputum eosinophils, we could argue that uEPX might
provide additional information on activity of eosinophilic
airway in�ammation. However, the correlations were weak
and the scatter of individual uEPX values wide. erefore, it
seems unlikely that uEPX will be useful as a biomarker for
monitoring asthma in the individual child.
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